Which health outcomes is the study assessing?
Half of the study participants will get tablets containing semaglutide and half will get inactive placebo tablets which look like the semaglutide tablets but have no active drug in them.
At the end of the study we will see how many people in each group suffered a serious heart or circulation problem. These conditions include:
- heart attacks, strokes or mini strokes (also known as transient ischaemic attacks or TIA)
- death from heart or circulatory problems
- the need for a stent or bypass surgery to treat a blocked heart artery.
This information will be analysed to find out if oral semaglutide truly does reduce the risk of people with type 2 diabetes developing these conditions.
Oral semaglutide could also potentially reduce the risk of people with type 2 diabetes from developing other health problems related to diabetes, such as kidney disease and long-term memory problems including dementia. The ASCEND PLUS research team will investigate this.